Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
Introduction and objectives: Hepatocellular carcinoma (HCC) is the most common liver neoplasm worldwide. Pro-inflammatory and pro-fibrogenic processes are key in tumor development. On the other hand, Pirfenidone (PFD) has anti-inflammatory and antifibrogenic properties useful to counteract hepatocar...
Main Authors: | Hugo C. Monroy-Ramírez, Scarlet Arceo-Orozco, Araceli G. Rivera-Cabral, Marina Galicia-Moreno, Juan Armendáriz-Borunda |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Annals of Hepatology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124001959 |
Similar Items
-
Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2024-02-01) -
Pirfenidone Reverts Global DNA Hypomethylation, Promoting DNMT1/UHRF/PCNA Coupling Complex in Experimental Hepatocarcinoma
by: Hipolito Otoniel Miranda-Roblero, et al.
Published: (2024-06-01) -
Binding to nucleosome poises human SIRT6 for histone H3 deacetylation
by: Ekaterina Smirnova, et al.
Published: (2024-02-01) -
Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01) -
Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.
by: Fernando Caloca-Camarena, et al.
Published: (2024-02-01)